Abstract
In 2000, the da Vinci Surgery System was approved by the United States Food and Drug Administration for general laparoscopic surgery and it became the first commercially available robotic surgery system. The aim of this study was to identify the incidence of postoperative pulmonary complications (PPCs) in patients undergoing da Vinci surgery and to observe whether the incidence of PPCs was affected by the usage of Sugammadex. Sugammadex is a gamma-cyclodextrin that encapsulates and subsequently inactivates steroidal neuromuscular blocking agents. A retrospective study was conducted on patients who had undergone da Vinci surgery in a single medical center in southern Taiwan during the period from January 2018 to December 2018. We extracted data on patient characteristics, usage of Sugammadex and PPCs for analysis. Three hundred and thirty-three patients were enrolled in the final analysis. While the overall incidence of PPCs was 30.3% (101/333 patients), the incidence of PCC in patients who received Sugammadex (24.2%) was significantly lower than those without (37.3%) (p = 0.001). Risk factors that appeared to be closely associated with PCC included age, malignancy, hypertension, chronic kidney disease, blood loss amount and anemia. The use of Sugammadex decreased the risk of PPC. In order to enhance early recovery after da Vinci surgery, the use of Sugammadex to rapidly reverse muscle relaxants may be an appropriate choice.
Highlights
Data extracted from the electronic medical records included age, gender, malignancy, tobacco/cigarette use, body mass index, American Society of Anesthesiologists (ASA) physical status, chronic illness such as diabetes mellitus (DM), hypertension, chronic kidney disease (CKD), coronary artery disease history (CAD), asthma, chronic obstructive pulmonary disease and stroke, laboratory data such as hematocrit and creatinine, length of hospital stay, post-anesthesia care unit stay time, blood transfusion units and pulmonary complications (PPCs)
Our data showed that the use of Sugammadex could decrease the risk of PPCs and shorten the hospital stay in patients undergoing da Vinci surgery
The PPCs rate was 30.3% after da Vinci surgery, which is similar to this multicenter study, but is relatively high compared to most previous studies [9]
Summary
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. Robotic-assisted surgery with the da Vinci Surgical System has been an advanced option in neurological, urological, gynecological, cardiothoracic, and numerous general surgical procedures since 2000. The benefits of the Surgical System include less abdominal access trauma, less postoperative pain, a shorter hospitalization period, quicker return to normal functioning and improved cosmetic effects [1,2,3]. The da Vinci Surgical System allows the surgeon’s hand movements to be scaled, filtered, and translated into the precise movements of the EndoWrist instruments
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
